RIG-I Promotes Tumorigenesis and Confers Radioresistance of Esophageal Squamous Cell Carcinoma by Regulating DUSP6Lu Li, Liting Qian|International Journal of Molecular Sciences|2023Cited by 4
A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).Ting Wang, Qing Zhou, Lin Huang et al.|Journal of Clinical Oncology|2024Cited by 3